Chief Heme/Onc fellow @Moffittnews, forever 🐊 via @ufimres| love all things myeloid | this account is an observation post for me and my cat.
Joined May 2021
- Tweets301
- Following517
- Followers366
- Likes1.9K
Pinned Tweet
I Had to Tell My Patient About His Cancer Every 10 Minutes opmed.doximity.com/articles/… via @doximity
Umar Iqbal, MD retweeted
Kinda feel bad for Ed Boyden & Zhuo-Hua Pan
Who's Zhuo-Hua Pan? See
statnews.com/2016/09/01/opto…
BREAKING NEWS
The 2026 #NobelPrize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel “for their discoveries concerning light-gated ion channels and optogenetics.”
The micro-environment at Houston was very hostile to dysplastic myeloid clones. #soho26
Umar Iqbal, MD retweeted
We're delighted to welcome our newest ⭐ class of hematology oncology fellows to @MoffittNews 🎉. Smiles all around as they kick off their journey with a comprehensive orientation month. We can't wait to see all they'll accomplish. Welcome to the Moffitt family!
Beautiful read.
🎉 BLR is thrilled to announce that “Two Thoracotomies” by Angela Tang-Tan has won a @PushcartPrize! Angela’s essay—from BLR Issue 49, our "Animalia" issue—parallels her experience in a research lab with a devastating overnight shift in the emergency room. blreview.org/news/recent-new…
334
Our gentle giant logging off from PD duties after a decade of shepherding @MoffittNews Onc fellowship.
We crowned him as the “Greatest PD of all time!” (settled science, fact!)
As Henry Adams said - “A teacher affects eternity.” True indeed.
Umar Iqbal, MD retweeted
Another creative idea in cancer therapy lately...
A new @NatureMedicine * study transplanted CRISPR-edited donor stem cells with CD33 removed into patients with high-risk AML. Because the new marrow lacks CD33, a CD33-targeted drug (gemtuzumab) can then wipe out residual leukemia without harming the healthy donor cells.✅
All 30 patients engrafted (median 10 days). Relapse-free survival 14 months in a population where outcomes are usually much worse.
Still early and intensive, but the idea is exciting: engineering normal tissue so cancer therapy can be more selective and safer.
Check out this labor of love, a patient focused app for All things myeloma!
By the very patient outcome focused Dr. Neupane!
Umar Iqbal, MD retweeted
Check our viewpoint published @JAMA_current #MedEd
Abstract Factory—Research Culture Harming Medical Education
The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs, diluted conferences. We shouldn't celebrate this—you don't need publications to be a great doctor.
➡️jamanetwork.com/journals/jam…
@utswcancer @rajshekharucms @HiraSMian @ManniMD1 @HemOncFellows @ASCOTECAG
Umar Iqbal, MD retweeted
At #ASH25: Umar Iqbal, MD (@umariqbalmed) presents early real-world data for revumenib confirming good tolerability with no adverse events leading to discontinuations. He shares that early efficacy data shows excellent activity across molecular and disease subsets.
#MoffittASH25 @ASH_hematology
Umar Iqbal, MD retweeted
Spotted some of our hematology oncology fellows tonight at the #ASH25 poster session! #MoffittASH25
Umar Iqbal, MD retweeted
Huge congratulations to Amir Fathi for delivering one of the most impactful plenary presentations @ASH_hematology in AML in past decade. The PARADIGM study may lead to a Paradigm shift- Aza/Ven > intensive chemo in newly Dx high-risk AML. 👏👏👏
Umar Iqbal, MD retweeted
Umar Iqbal, MD (@umariqbalmed) shares early real-world data of the efficacy and tolerability of revumenib outside of a clinical trial setting.
#MoffittASH25 @ASH_hematology
Umar Iqbal, MD retweeted
“When you are dying, at least in my limited experience, you start remembering everything.” Tatiana Schlossberg, the daughter of Caroline Kennedy, writes about receiving a terminal diagnosis. newyorkermag.visitlink.me/4S…
What comes after trials? Excited to share our early real world revumenib experience at ASH! Seems like AML armamentarium is broadening well.
Umar Iqbal, MD retweeted
Come join Nevada's first BMT/cell therapy!
We are already super successful. We need another doc.
I can only last so long doing Q2week call! We are helping patients in great need.
I have never asked for a retweet, but colleagues please retweet.
tinyurl.com/4zew3wab
Umar Iqbal, MD retweeted
Just to recap:
We found out today that an LLM that fits on a high-end consumer GPU, when trained on specific biological data, can discover a novel method to make cancer tumors more responsive to immunotherapy.
Confirmed novel discovery (not present in existing literature). Experimentally validated in living cells.
This is AI generating novel science. The moment has finally arrived.
Google and Yale scientists have trained an LLM that has generated a novel hypothesis about cancer cellular behavior. This prediction was confirmed multiple times in vitro.
- "What made this prediction so exciting was that it was a novel idea. Although CK2 has been implicated in many cellular functions, including as a modulator of the immune system, inhibiting CK2 via silmitasertib has not been reported in the literature to explicitly enhance MHC-I expression or antigen presentation. This highlights that the model was generating a new, testable hypothesis, and not just repeating known facts."
The model that generated this prediction is a 27B-parameter LLM based on the Google Gemma open source models, and trained on a corpus comprising >1B tokens of transcriptomic data, biological text, and metadata. Quite remarkable that a small (just 27B) LLM trained on specialized data is able to make novel scientific discoveries.
"Teams at Yale are now exploring the mechanism uncovered here and testing additional AI-generated predictions in other immune contexts. With further preclinical and clinical validation, such hypotheses may be able to ultimately accelerate the path to new therapies."